US EditionGlucotrack gains HREC approval for clinical study of CBGM device
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Glucotrack gains HREC approval for clinical study of CBGM device
Glucotrack has announced the receipt of St Vincent’s Hospital Melbourne HREC approval for a CBGM study for types 1 and 2 diabetes.The post Glucotrack gains HREC approval for clinical study of CBGM device appeared first on Medical Device Network.
Glucotrack can proceed with long-term glucose monitor study
Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New Jersey-based Glucotrack develops the CBGM implant that features no on-body external …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
